-
Yiu, EM, Tai, G, Peverill, RE, Lee, KJ, Croft, KD, Mori, TA, Scheiber-Mojdehkar, B, Sturm, B, Praschberger, M, Vogel, AP, et al.
An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels..
J Neurol
262(5)
:
1344 -1353
2015
view publication
-
Pandolfo, M, Arpa, J, Delatycki, MB, Le Quan Sang, KH, Mariotti, C, Munnich, A, Sanz-Gallego, I, Tai, G, Tarnopolsky, MA, Taroni, F, et al.
Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial..
Ann Neurol
76(4)
:
509 -521
2014
view publication
-
Delatycki, MB, Tai, G, Corben, L, Yiu, EM, Evans-Galea, MV, Stephenson, SEM, Gurrin, L, Allen, KJ, Lynch, D, Lockhart, PJ.
HFE p.C282Y heterozygosity is associated with earlier disease onset in Friedreich ataxia..
Mov Disord
29(7)
:
940 -943
2014
view publication
-
Corben, LA, Ho, M, Copland, J, Tai, G, Delatycki, MB.
Increased prevalence of sleep-disordered breathing in Friedreich ataxia..
Neurology
81(1)
:
46 -51
2013
view publication
-
Yiu, E, Tai, G, Peverill, R, Lee, K, Croft, K, Mori, T, Stephenson, S, Lockhart, P, Sarsero, J, Churchyard, A, et al.
An Open Label Clinical Pilot Study of Resveratrol as a Treatment for Friedreich Ataxia (S43.006).
Neurology
80(7_supplement)
:
2013
view publication